Medicus Pharma ($MDCX) Executive Chairman on SkinJect™, Teverelix®, and What's Next

Medicus Pharma ($MDCX) is a clinical-stage biotech developing SkinJect for basal cell carcinoma and Teverelix for prostate cancer and BPH.

Dr. Raza Bokhari outlines Phase 2 clinical trial strategies and anticipated 2026 milestones, emphasizing a multi-program portfolio approach.

The company is actively pursuing strategic partnerships and target acquisitions to expand its therapeutic pipeline and build long-term shareholder value.